Eaton Vance Management decreased its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 1.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 68,746 shares of the medical instruments supplier’s stock after selling 1,111 shares during the period. Eaton Vance Management owned approximately 0.35% of ICU Medical worth $11,859,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of ICUI. Creative Planning boosted its holdings in shares of ICU Medical by 315.6% during the 1st quarter. Creative Planning now owns 665 shares of the medical instruments supplier’s stock valued at $102,000 after acquiring an additional 505 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of ICU Medical by 10.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 707 shares of the medical instruments supplier’s stock valued at $122,000 after acquiring an additional 66 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of ICU Medical by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 1,050 shares of the medical instruments supplier’s stock valued at $181,000 after acquiring an additional 157 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new stake in shares of ICU Medical during the 1st quarter valued at $194,000. Finally, Parametrica Management Ltd acquired a new stake in shares of ICU Medical during the 2nd quarter valued at $213,000. Institutional investors own 78.13% of the company’s stock.
Shares of ICU Medical, Inc. (NASDAQ:ICUI) opened at 179.95 on Tuesday. The firm has a market cap of $3.57 billion, a P/E ratio of 72.07 and a beta of 0.36. ICU Medical, Inc. has a 12-month low of $120.14 and a 12-month high of $180.15. The company’s 50 day moving average price is $171.38 and its 200 day moving average price is $162.99.
ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by $0.06. ICU Medical had a net margin of 6.10% and a return on equity of 7.56%. The business had revenue of $331.51 million for the quarter, compared to analysts’ expectations of $318.30 million. During the same quarter in the previous year, the company earned $1.15 earnings per share. The business’s quarterly revenue was up 242.8% on a year-over-year basis. Equities research analysts forecast that ICU Medical, Inc. will post $4.11 EPS for the current year.
In other ICU Medical news, Chairman Vivek Jain sold 100,000 shares of the company’s stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $170.80, for a total transaction of $17,080,000.00. Following the completion of the sale, the chairman now directly owns 110,925 shares in the company, valued at $18,945,990. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Scott E. Lamb sold 2,998 shares of the company’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $170.13, for a total transaction of $510,049.74. Following the sale, the chief financial officer now owns 9,050 shares of the company’s stock, valued at $1,539,676.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 212,549 shares of company stock valued at $36,354,740. Company insiders own 15.90% of the company’s stock.
Several equities research analysts recently weighed in on ICUI shares. Zacks Investment Research raised ICU Medical from a “hold” rating to a “buy” rating and set a $193.00 price objective on the stock in a report on Thursday, July 20th. Gabelli reissued a “buy” rating on shares of ICU Medical in a report on Friday, August 11th. BidaskClub raised ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, June 17th. Finally, Sidoti downgraded ICU Medical from a “buy” rating to a “neutral” rating in a report on Tuesday, June 20th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. ICU Medical has an average rating of “Hold” and a consensus price target of $193.00.
About ICU Medical
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI).
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.